MondayNightIBD
Evolving Treatment Targets and Monitoring Strategies in Crohn's Disease
October 14, 2024 ~ Jami Kinnucan, MD
Post-Survey & Application for CME Credit

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.

Question Title

* 1. What are your specialty & credentials?

IBD Specialist

General GI

Colorectal Surgeon

Fellow/Trainee

APP

Nurse

PharmD

Other (please specify)

Question Title

* 2. What is your community of practice?

Academic

Community

Industry

Other (please specify)

Question Title

* 3. According to STRIDE-II, which of the following is considered an intermediate treatment target for IBD?

Endoscopic healing

Normalization of CRP

Normalization of quality of life

Symptomatic improvement

Question Title

* 4. A 32-year-old woman with newly diagnosed Crohn’s ileocolitis is started on ustekinumab and achieves endoscopic healing at year 1 with some pseudopolyps in right colon and a short non-obstructing fibrotic stenosis at the ileocaecal valve.

Which of following is a long term T2T for her?

Prevent disability

Reverse fibrosis

Treat the pseudopolyps

Be able to stop therapy

EVALUATION FORM

Question Title

* 5. Upon completion of this activity, I am able to:

	Strongly agree	Agree	Disagree	Strongly disagree
Utilize best practices and data supporting treat-to-target approach for optimized care of patients with Crohn’s disease	Utilize best practices and data supporting treat-to-target approach for optimized care of patients with Crohn’s disease Strongly agree	Utilize best practices and data supporting treat-to-target approach for optimized care of patients with Crohn’s disease Agree	Utilize best practices and data supporting treat-to-target approach for optimized care of patients with Crohn’s disease Disagree	Utilize best practices and data supporting treat-to-target approach for optimized care of patients with Crohn’s disease Strongly disagree

Question Title

* 6. Please indicate the extent of your agreement with the following statements:

	Strongly agree	Agree	Disagree	Strongly disagree
The faculty for this activity were effective	The faculty for this activity were effective Strongly agree	The faculty for this activity were effective Agree	The faculty for this activity were effective Disagree	The faculty for this activity were effective Strongly disagree

Question Title

* 7. Overall, was this activity fair, balanced and free from commercial bias?

Yes

Question Title

* 8. If no, please explain:

Question Title

* 9. Of the patients with IBD you will see in the next month, about how many will benefit from the information you learned today?

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 10. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Identify patients at a high-risk of progressive disease

Appropriately assess disease activity

Apply STRIDE-II recommendations to treatments plans

Initiate advanced therapies earlier for patients at high-risk of progression

Utilize tight control treatment strategies

Individualize treatment targets using objective targets of disease control and work with patients to identify which targets are important to them

I do not plan on making changes to my practice at this time

Other (explain)

Question Title

* 11. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Lack of knowledge regarding treatment options (patient-related)

Patient adherence/resistance to new therapeutics and/or clinical trial enrollment (patient-related barrier)

Limited knowledge regarding new therapeutics for <insert disease state here> (provider-level barrier)

Lack of time resources to consider change (practice-related barrier)

Inadequate support staff for pt education/insurance/billing/administrative issues (practice-level barrier)

Insurance reimbursement or legal issues (systems-related barrier)

Lack of access to novel therapeutics due to regulatory approvals/insurance coverage (systems-related barrier)

Other (please specify)

Question Title

* 12. For purposes of certification, you must complete the following information.
Please note that we will not forward or sell your contact information.

First Name *

Last Name *

Degree/Credentials:

City

State/Province

ZIP/Postal Code *

Country

Email Address (required to receive credit) *

Question Title

* 13. I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | Evolving Treatment Targets & Monitoring Strategies in Crohn's Disease" and claim 0.5 AMA PRA Category 1 Credit^TM.

Yes

Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate.

For additional information about the accreditation of this activity, please visit https://www.partnersed.com

MondayNightIBD Evolving Treatment Targets and Monitoring Strategies in Crohn's DiseaseOctober 14, 2024 ~ Jami Kinnucan, MD***Post-Survey & Application for CME Credit***

Question Title

* 1. What are your specialty & credentials?

Question Title

* 2. What is your community of practice?

Question Title

* 3. According to STRIDE-II, which of the following is considered an intermediate treatment target for IBD?

Question Title

* 4. A 32-year-old woman with newly diagnosed Crohn’s ileocolitis is started on ustekinumab and achieves endoscopic healing at year 1 with some pseudopolyps in right colon and a short non-obstructing fibrotic stenosis at the ileocaecal valve.Which of following is a long term T2T for her?

Question Title

* 5. Upon completion of this activity, I am able to:

Question Title

* 6. Please indicate the extent of your agreement with the following statements:

Question Title

* 7. Overall, was this activity fair, balanced and free from commercial bias?

Question Title

* 8. If no, please explain:

Question Title

* 9. Of the patients with IBD you will see in the next month, about how many will benefit from the information you learned today?

Question Title

* 10. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Question Title

* 11. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Question Title

* 12. For purposes of certification, you must complete the following information. *Please note that we will not forward or sell your contact information.*

Question Title

* 13. I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | Evolving Treatment Targets & Monitoring Strategies in Crohn's Disease" and claim 0.5 AMA PRA Category 1 CreditTM.

MondayNightIBD
Evolving Treatment Targets and Monitoring Strategies in Crohn's Disease
October 14, 2024 ~ Jami Kinnucan, MD
Post-Survey & Application for CME Credit

* 4. A 32-year-old woman with newly diagnosed Crohn’s ileocolitis is started on ustekinumab and achieves endoscopic healing at year 1 with some pseudopolyps in right colon and a short non-obstructing fibrotic stenosis at the ileocaecal valve.

Which of following is a long term T2T for her?

* 12. For purposes of certification, you must complete the following information.
Please note that we will not forward or sell your contact information.

* 13. I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | Evolving Treatment Targets & Monitoring Strategies in Crohn's Disease" and claim 0.5 AMA PRA Category 1 Credit^TM.